在COPD中使用的吸入器的气溶羽毛
Herbert Wachtel1, Rachel Emerson-Stadler2, Peter Langguth3
1Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany. herbert.wachtel@boehringer-ingelheim.com.
Pulmonary therapy
|January 9, 2024
概括
在COPD治疗中,软雾吸入器 (SMIs) 与压力计量剂量吸入器 (pMDIs) 和干粉吸入器 (DPIs) 相比,在较长时间内释放更慢的气溶. 吸入器类型显著影响气溶的特性,影响药物输送.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 制药技术 制药技术 制药技术
- 生物医学工程 生物医学工程
背景情况:
- 在慢性阻塞性肺病 (COPD) 中,吸入器设备的选择对于有效的药物输送和肺部沉积至关重要.
- 患者的吸入概况与气溶特性相互作用,影响治疗结果.
- 本研究评估了用于COPD的各种吸入器类型的体外气溶特性.
研究的目的:
- 为了比较COPD治疗的不同吸入器设备的体外气溶特性.
- 评估气溶羽流速对软雾吸入器 (SMIs),压力计量剂量吸入器 (pMDIs) 和干粉吸入器 (DPI) 气溶羽流速度和持续时间的影响.
主要方法:
- 高速视频录制用于测量9个吸入器的气溶速度和喷雾持续时间 (1个SMI,3个pMDIs,5个DPI).
- 吸入器含有长效支气管扩展剂和吸入性皮质类固醇的固定剂量组合.
- 测量在实验流速为30,60和90L/分钟时进行,并根据最佳药典流速进行比较.
主要成果:
- 该SMI表现出明显较慢的羽毛速度 (0.99 m/s) 和较长的喷雾持续时间 (1447 ms) 比pMDIs和DPIs.
- DPI显示速度在1.43-4.60m/s和持续时间在60-757ms之间;pMDIs的速度在3.65-5.09m/s和持续时间在227-270ms之间.
- 增加流量增加了SMI和DPI羽流速度,但对pMDIs的影响很小;持续时间的影响是可变的.
结论:
- 在COPD的不同类型的吸入器中,气溶速度和羽毛持续时间存在显著差异.
- 与pMDIs和DPIs相比,SMI显示出不同的气溶特性 (速度较慢,持续时间较长).
- 流速影响SMI和DPI羽流速度,强调了将吸入器与患者吸入容量相匹配的重要性.
相关概念视频
Inhaled Medications
271
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
271
COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Drugs Used in Lower Respiratory Disorders: Overview
445
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
445


